Scientific Programme

Wednesday, 7 December 2022

8:30-9:30

UCARE business meeting

8:30-10:00

Registration 

10:00-10:15

Welcome, introduction and objectives
Ana Giménez-Arnau (Spain)
Torsten Zuberbier (Germany)
Marcus Maurer (Germany)

10:15-10:45

Recurrent mast cell mediated angioedema without wheals – what are we missing?
Marta Ferrer (Spain) & Markus Magerl (Germany)

Oral Presentation Session I: The aetiopathogenesis of urticaria

10:45-11:05

Causes of chronic urticaria – Open questions
and how to answer them
Allen Kaplan (USA) & Riccardo Asero (Italy)

11:05-11:14

OP.001 Mast cell-derived GM-CSF and physical interaction in the skin promotes bidirectional mast cell-eosinophil activation
Stefan Frischbutter (Germany)

11:14-11:23

OP.002  Transcriptome analysis of experimentally-induced wheals in patients with cold urticaria
Nasser Mohammad-Porras (Spain)

11:23-11:32

OP.003 The significant changes in the gene expression of STAT3, IL-27, and IL-35 in patients with chronic spontaneous urticaria
Maryam Khoshkhui (Iran)

11:32-11:41

OP.004 The role of skin chemokines in the pathogenesis of CSU
Elias Toubi (Israel)

11:41-11:50

OP.005  Investigating endothelial dysfunction in chronic spontaneous urticaria
Katie Ridge (Ireland)

11:50-12:15

sponsored Coffee Break 

EMBRN Session: 
The biology of mast cells and basophils and their role in health and disease

12:15-12:20

Introduction
Francesca Levi-Schaffer (Israel)

12:20-12:45

 

 

12:45-13:10

Development of an anti-IgE vaccine for the treatment of IgE- and mast cell/basophil-mediated diseases
Laurent Reber (France)


Autoreactive IgE and basophils in autoimmunity
Nicolas Charles (France)

13:10-13:15

Discussion and Q&A
Francesca Levi-Schaffer (Israel)

13:15-14:20

Lunch Break

Oral Presentation Session II: Differential diagnosis, comorbidities, diagnostic approaches and biomarkers

14:20-14:40

The diagnostic workup of chronic urticaria – Dos and Don’ts
Karla Arruda (Brazil) & Constance Katelaris (Australia)

14:40-14:49

OP.006  Cold urticaria and anaphylaxis are associated with hereditary α-tryptasemia and KIT p.D816V
Mojca Bizjak (Slowenia)

14:49-14:58

OP.007  PREDICT-CU: Predicting time to clinical remission in chronic urticaria
Maria-Magdalena Balp (Switzerland)

14:58-15:07

OP.008  Remibrutinib inhibits mastcell and basophil activation in chronic urticaria independently of FcεR1 expression
Ana Giménez-Arnau (Spain)

14:07-15:16

OP.009  Urticaria in patients with suspected mast cell activation syndrome
Fabiana Nunes Oliveira (Brazil)

14:16-15:25

OP.010  In chronic spontaneous urticaria, fever, pain and malaise are common and linked to active and uncontrolled disease: Results from the Chronic Urticaria Registry (CURE)
Polina Pyatilova (Germany)

15:25-15:55

Assessing CU patients for biomarkers and disease
status – How to harmonize our approach

Ana Giménez-Arnau (Spain) & Pavel Kolkhir (Germany)

15:55-16:20

sponsored Coffee Break 

Workshop

16:20-16:27

Introduction and overview over past UCARE Projects
Ana Giménez-Arnau (Spain) & Marcus Maurer (Germany)

16:27-17:03

Quick Presentations of current and upcoming UCARE Projects 
Project Leaders

17:03-17:13

Presentation of CURE and CRUSE Control
Yana Hackler, Karsten Weller & Sophia Neisinger (Germany)

17:13-17:20

Discussion, Questions and Wrap-up
Ana Giménez-Arnau (Spain) & Marcus Maurer (Germany)

Oral Presentation Session III: Urticaria treatments and predictors of response

17:20-17:40

Findings from recent and ongoing urticaria studies and trials
Torsten Zuberbier (Germany) & Emek Kocatürk (Turkey)

17:40-17:49

OP.011 Remibrutinib for Chronic Spontaneous Urticaria: Time to Complete Urticaria Control
Petra Staubach-Renz (Germany)

17:49-17:58

OP.012 Long-term safety of remibrutinib in CSU patients: Phase 2b study
Ana Giménez-Arnau (Spain)

17:58-18:07

OP.013 Dupilumab Efficacy in Patients with Chronic Spontaneous Urticaria with Comorbidities
Marcus Maurer (Germany)

18:07-18:16

OP.014 Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab
Dorothea Terhorst-Molawi (USA)

18:16-18:25

OP.015 Elevated levels of soluble FcεRI as a biomarker of early and good response to omalizumab treatment in chronic spontaneous urticaria
Sherezade Moñino-Romero (Germany)

18:25-18:34

OP.016 Differences between pediatric and adult urticaria: patient characteristics, treatment response and indicators of response
Sinem Ornek Ozdemir (Turkey)

18:34-18:43

OP.017 Autoimmunity and low IgE in CSU: a prospective analysis
David Pesqué (Spain)

18:43-18:52

OP.018 Anti-TPO/total IgE ratio – biomarker for omalizumab response prediction in CSU
Rita Brás (Portugal)

18:52-19:00

Closing remarks
Ana Giménez-Arnau (Spain)
Torsten Zuberbier (Germany)
Marcus Maurer (Germany)

19:00

Scientific Dinner Reception
Langenbeck-Virchow-Haus

Thursday, 8 December 2022

07:15-08:30

Registration 

08:30-08:45

Welcome
Ana Giménez-Arnau (Spain)
Torsten Zuberbier (Germany)
Marcus Maurer (Germany)

Oral Presentation Session IV: Treatment of urticaria

08:45-09:05

Current and novel treatment targets and approaches
Martin Metz (Germany) & Sarbjit Saini (USA)

09:05-09:14

OP.019 Multi-dosed barzolvolimab is effective in chronic spontaneous urticaria
Marcus Maurer (Germany)

09:14-09:23

OP.020 Treatment with MRGPRX2 Antagonist EP262 Potently Inhibits Mast Cell Degranulation 
Veena Viswanath (USA)

09:23-09:32

OP.021 Remibrutinib improves CSU in patients with low or high IgE
Michihiro Hide (Japan)

09:32-09:41

OP.022 Anti-IL-23 treatment in patients with omalizumab-refractory chronic spontaneous urticaria – a case series
Hanna Bonnekoh (Germany)

09:41-09:50

OP.023 Omalizumab drug survival for chronic urticaria – the DruSO-CU UCARE study
Reineke Soegiharto (The Netherlands)

09:50-09:59

OP.024 CRUSE – What the first 100 days have taught us
Sophia Neisinger (Germany)

10:00-11:10

Poster Session

11:10-11:50

Coffee Break    


Interactive Case Journey

11:50-13:00

Problems you like, solutions you’re looking for –
An interactive patient journey
Facilitators: Karoline Krause (Germany) & Frank Siebenhaar (Germany)

13:00-14:30

sponsored Lunch Break

ACARE Session: Recurrent angioedema

14:30-14:35

Introduction 
Markus Magerl (Germany)

14:35-14:48

Erythema marginatum as initial phase of an hereditary angioedema attack
Kinga Viktoria Kohalmi (Hungary)

14:48-15:01

Importance of the complement test in patients with angioedema taking  ACE inhibitor
Henriette Farkas (Hungary)

15:01-15:14

The use of anti-IgE therapy to define idiopathic non-histaminergic angioedema
Jason Fok (Australia)

15:14-15:27

Estrogen triggering non-hereditary Angioedema
Anete Grumach (Brazil)

15:27-15:40

ACARE projects and activities
Markus Magerl (Germany)

Closing Session

15:40-16:10

The future of urticariology – What are the unmet needs we need to address and how will we do this
Marcus Maurer (Germany) & Jonathan Bernstein (USA)

 

16:10-16:20

Closing remarks 
Ana Giménez-Arnau (Spain)
Torsten Zuberbier (Germany)
Marcus Maurer (Germany)

 

Industry Session

Thursday, 8 Decemeber 2022

07:30-08:15

Sponsored Breakfast Symposium
Type 2 Inflammation in CSU: Emerging Evidence and Implications

Impressions hybrid GUF 2022
Cooperating Organisations
Professional Congress Organiser

Remember Management GmbH
Albrechtstr. 14 b, D-10117 Berlin
Phone: +49 30 47 37 25 77
E-mail: guf@remember-management.de
www.remember-management.de